BioNTech shares fall more than 10% in pre-market trading

BioNTech shares fall more than 10% in pre-market trading

格隆汇

格隆汇2026/08/28 13:15

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Golden Ten Data August 28 | BioNTech SE (BNTX.US) is down over 10% in pre-market trading, quoted at $99.97. The company announced the termination of Phase 2 Cevumeran cancer immunotherapy trial.

0

0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

You may also like

Cambria Gold Mines management says Q2 2026 loss narrows on absence of prior-year C$324.4 million impairment charge

Reuters•2026/08/29 04:28

Cambria Gold Mines FY26 Q2 net loss narrows to CAD 2.96 million

Reuters•2026/08/29 04:28

TRUMP rises nearly 8% in 24 hours, market capitalization reaches $2.037 billions

BlockBeats•2026/08/29 04:20

Electra Therapeutics (ETRA.US) submits US IPO application, leveraging the biotech IPO boom to advance new drug development for immune diseases and cancer.

Electra Therapeutics Inc. has officially filed for an initial public offering (IPO), aiming to leverage the strong IPO performance of the biotechnology sector this year to raise funds for its clinical-stage pipeline of drugs targeting immune-mediated diseases and cancer.

智通财经•2026/08/29 03:22

Electra Therapeutics (ETRA.US) submits US IPO application, leveraging the biotech IPO boom to advance new drug development for immune diseases and cancer.

Crypto prices

Bitget lists BTC – Buy or sell BTC quickly on Bitget!

Become a trader now?A welcome pack worth 6200 USDT for new users!